1.95

0.51% 0.015

Rezolute Inc (RZLT)

Overview News Price History Financials Discussions Forecast Stock Split

Rezolute Inc stock is traded at $1.95, with a volume of 453.99K. It is up +0.51% in the last 24 hours and down -81.05% over the past month. Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Previous Close:

$1.965

Open:

$2.01

24h Volume:

453.99K

Relative Volume:

0.08

Market Cap:

$180.82M

Revenue:

Net Income/Loss:

$-69.31M

P/E Ratio:

-1.5354

EPS:

-1.27

Net Cash Flow:

$-62.80M

1W Performance:

-9.82%

1M Performance:

-81.05%

6M Performance:

-59.02%

1Y Performance:

-62.09%

1-Day Range:

$1.92

$2.015

1-Week Range:

$1.92

$2.43

52-Week Range:

$1.07

$11.46

Rezolute Inc Stock (RZLT) Company Profile

Name

Rezolute Inc

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

650-206-4507

Address

275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2025-09-17

Latest SEC Filings

RZLT's Discussions on Twitter

Compare RZLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RZLT Rezolute Inc	1.95	182.21M	0	-69.31M	-62.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	465.71	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.49	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	391.77	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.47	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Aug-27-24	Initiated	Guggenheim	Buy
Jul-17-24	Initiated	BTIG Research	Buy
Jun-04-24	Initiated	Craig Hallum	Buy
Apr-09-24	Initiated	Maxim Group	Buy
Aug-02-22	Resumed	Canaccord Genuity	Buy
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight
Sep-08-21	Initiated	ROTH Capital	Buy
May-27-21	Initiated	Oppenheimer	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy

View All

Rezolute Inc Stock (RZLT) Latest News

03:26 AM

Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

03:26 AM

Jan 03, 2026

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - GlobeNewswire

Jan 03, 2026

Rezolute’s Phase 3 SunRIZE study for Ersodetug fails to meet primary and secondary endpoints despite analyst backing - MSN

Jan 03, 2026

Shareholders Alert: Investigation Into Rezolute, Inc. (RZLT) – Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jan 03, 2026

Jan 02, 2026

Investigation Underway: Rezolute, Inc. (RZLT)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire

Jan 02, 2026

Jan 01, 2026

Weekly Trades: Will Rezolute Inc 6HV1 stock test record highs in 20252025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - moha.gov.vn

Jan 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - PR Newswire

Jan 01, 2026

Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN

Jan 01, 2026

Dec 31, 2025

Revenue per share of Rezolute, Inc. – FWB:6HV1 - TradingView — Track All Markets

Dec 31, 2025

Investors in Rezolute, Inc. (RZLT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

Dec 31, 2025

Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Finviz

Dec 31, 2025

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT - The Malaysian Reserve

Dec 31, 2025

Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing - Insider Monkey

Dec 31, 2025

Rezolute Faces Legal Scrutiny Following Disastrous Clinical Trial Results - timothysykes.com

Dec 31, 2025